U-Neuron Biomedical (ROCO:6973) EBITDA Margin %: -52.65% (As of Dec. 2025)


ROCO:6973 U-Neuron Biomedical Inc ROCO:6973
12 GF Score
Price NT$33.75
! 2 Warning Signs
View Full Analysis

What is U-Neuron Biomedical EBITDA Margin %?

U-Neuron Biomedical ROCO:6973 12 EBITDA Margin % is -52.65% as of Dec. 2025. GuruFocus rates ROCO:6973 with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 939 Biotechnology companies, U-Neuron Biomedical ranks better than 52.4% on this metric.

EBITDA Margin % is calculated as EBITDA divided by its Revenue. U-Neuron Biomedical's EBITDA for the six months ended in Dec. 2025 was NT$-22.42 Mil. U-Neuron Biomedical's Revenue for the six months ended in Dec. 2025 was NT$42.58 Mil. Therefore, U-Neuron Biomedical's EBITDA margin for the quarter that ended in Dec. 2025 was -52.65%.

U-Neuron Biomedical  (ROCO:6973) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

U-Neuron Biomedical EBITDA Margin % Related Terms

U-Neuron Biomedical EBITDA Margin % Historical Data

* Premium members only.

The historical data trend for U-Neuron Biomedical's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

U-Neuron Biomedical EBITDA Margin % Chart

U-Neuron Biomedical Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBITDA Margin %
Get a 7-Day Free Trial -33.84 -136.35 -288.17 -111.35 -48.56

U-Neuron Biomedical Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only -168.13 -135.88 -91.26 -44.23 -52.65

ROCO:6973 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison

For the Biotechnology subindustry, U-Neuron Biomedical's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

U-Neuron Biomedical EBITDA Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, U-Neuron Biomedical's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where U-Neuron Biomedical's EBITDA Margin % falls into.


ROCO:6973
12GF Score
U-Neuron Biomedical Inc ROCO:6973
EBITDA Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

U-Neuron Biomedical EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

U-Neuron Biomedical's EBITDA Margin % for the fiscal year that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-40.145/82.663
=-48.56 %

U-Neuron Biomedical's EBITDA Margin % for the quarter that ended in Dec. 2025 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2025 )/Revenue (Q: Dec. 2025 )
=-22.417/42.579
=-52.65 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBITDA Margin % →
What does a EBITDA Margin % of -52.65% mean?
U-Neuron Biomedical (ROCO:6973) has a EBITDA Margin % of -52.65% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on U-Neuron Biomedical and its competitors. According to the industry distribution chart, U-Neuron Biomedical ranks #447 out of 939 companies in the Biotechnology industry, placing it in the top 47.6%.
Is U-Neuron Biomedical's EBITDA Margin % too high?
U-Neuron Biomedical's current EBITDA Margin % is -52.65%. Based on the distribution chart, U-Neuron Biomedical ranks #447 out of 939 companies in the Biotechnology industry, which is above the industry midpoint. Overall, U-Neuron Biomedical has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does U-Neuron Biomedical's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, U-Neuron Biomedical ranks #447 out of 939 companies for EBITDA Margin %. This puts U-Neuron Biomedical in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on U-Neuron Biomedical and its competitors. U-Neuron Biomedical's current EBITDA Margin % is -52.65%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is U-Neuron Biomedical stock overvalued right now?
U-Neuron Biomedical (ROCO:6973) has a current EBITDA Margin % of -52.65%. The current EBITDA Margin % is -52.65%. U-Neuron Biomedical's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For U-Neuron Biomedical (ROCO:6973), the current EBITDA Margin % is -52.65% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

U-Neuron Biomedical Business Description

Address Xintai 5th Road, 18th Floor-5, No. 99, Section. 1, Xizhi District, New Taipei City, TWN, 22175
U-Neuron Biomedical Inc is engaged in research and development of stem cell storage & separation technology, and treatment application technology. It has patent on the Technology of Culture and Isolation of Amniotic Fluid Stem Cell.
12GF Score

Get the complete analysis for ROCO:6973

EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$33.75
Price